Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Ticker SymbolCDXS
Company nameCodexis Inc
IPO dateApr 22, 2010
CEOMoore (Alison)
Number of employees188
Security typeOrdinary Share
Fiscal year-endApr 22
Address200 Penobscot Dr
CityREDWOOD CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94063
Phone16504218100
Websitehttps://www.codexis.com/
Ticker SymbolCDXS
IPO dateApr 22, 2010
CEOMoore (Alison)
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data